Skip main navigation

Main contents starts here

More about Grange Castle

Located at the high technology Pharmaceutical and Biotechnology Business Park at Grange Castle in Clondalkin Dublin Takeda Ireland Ltd. (Grange Castle) is Takeda's first API plant constructed outside Japan.Takeda Ireland Grange Castle is a designated Centre of Excellence within the Takeda global manufacturing network for Active Pharmaceutical Ingredient (API) manufacturing, development and technical support. Grange Castle will also be the primary manufacturing source and supply of Ninlaro to global markets.Takeda Ireland Ltd - Grange Castle is a launch vehicle for new strategic products for global markets developing and producing API's, oncology and biologic drug products from clinical trial stages through to launch and full commercialisation. In our multipurpose API plant and new investment facilities we can supply new and established products, to world markets.

We rely on our world-class staff, equipment and systems to meet the challenge of competing in our leading edge markets. Our role includes responsibility for process R&D and technology transfer, which supplement our global supply requirements.

Company History & Future Plan
2002: Takeda Pharma Ireland Limited established
2002: Facility Design, Environmental Impact Study & Planning Permission
2003-2006: Construction, Commissioning & Validation of API Facility
2007: Start of commercial production
2008: FDA Approval
2009: Irish Medicines Board Wholesale License Approval
2009: Integration of Takeda Pharma Ireland Limited into Takeda Ireland Ltd. (Grange Castle)
2011: Completion of Administration Building Expansion
2017: Takeda Ireland Limited Grange Castle designated as a Centre of Excellence
2017: Construction of all-in-one API, DP and packaging facility for production of Ninlaro commences
2017: Planning permission sought for the construction of a biologics facility

Skip side navigation


Skip sub navigation

Page Top